{"id":"havrix-junior","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site soreness or swelling"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Loss of appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) hepatitis A virus antigen, which triggers the body's adaptive immune response to generate protective antibodies and cellular immunity against hepatitis A without causing disease. This provides long-term protection against infection with wild-type hepatitis A virus. The junior formulation contains a lower antigen dose suitable for pediatric populations.","oneSentence":"Havrix Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:31.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in children aged 12 months to 18 years"}]},"trialDetails":[{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120},{"nctId":"NCT03654664","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-06-20","conditions":"Hepatitis A Vaccine","enrollment":119},{"nctId":"NCT05613127","phase":"PHASE3","title":"To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs","status":"UNKNOWN","sponsor":"Boryung Biopharma Co., Ltd.","startDate":"2022-12","conditions":"Hepatitis A, Hep A","enrollment":106},{"nctId":"NCT01439360","phase":"PHASE3","title":"An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":"Influenza","enrollment":12046},{"nctId":"NCT01196026","phase":"PHASE4","title":"Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-15","conditions":"Influenza","enrollment":162},{"nctId":"NCT01379937","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-28","conditions":"Influenza","enrollment":520},{"nctId":"NCT01190215","phase":"PHASE4","title":"Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Influenza","enrollment":77},{"nctId":"NCT03183492","phase":"PHASE4","title":"Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-05-07","conditions":"Hepatitis A","enrollment":""},{"nctId":"NCT00544271","phase":"PHASE4","title":"Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2003-05","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":720},{"nctId":"NCT01405677","phase":"PHASE2","title":"Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2004-06","conditions":"Hepatitis A","enrollment":308},{"nctId":"NCT01349829","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2010-03","conditions":"Hepatitis A","enrollment":251}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CANCER PAIN"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"HEPATOCELLULAR INJURY"},{"count":1,"reaction":"HYPERBILIRUBINAEMIA"},{"count":1,"reaction":"NEOPLASM PROGRESSION"},{"count":1,"reaction":"OFF LABEL USE"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"RASH"},{"count":1,"reaction":"SOMNOLENCE"},{"count":1,"reaction":"VACCINATION SITE PAIN"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Havrix Junior","genericName":"Havrix Junior","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Havrix Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in children aged 12 months to 18 years.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}